Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot
CPT®
87802

CPT® Code 87802

Official Description

Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group B

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87802 refers to the detection of infectious agent antigens through an immunoassay method, specifically targeting the Streptococcus group B (Strep B). This group of bacteria is known to cause severe infections, particularly in vulnerable populations such as newborns, pregnant women, the elderly, and individuals with compromised immune systems. In newborns, Strep B can lead to life-threatening conditions including pneumonia, meningitis, and sepsis. In adults, especially pregnant women, it can result in serious infections like urinary tract infections, skin infections, and pneumonia. The primary purpose of this test is to screen for the presence of Strep B during pregnancy, allowing for timely intervention to prevent potential complications. The testing process involves obtaining a specimen through a swab of the cervix and lower third of the vagina, followed by the use of a rapid test kit designed to detect Strep B antigens. The procedure is dependent on the specific test kit used, but generally involves a series of reagent additions and observations to determine the presence of the antigen, ultimately providing critical information for the management of both maternal and neonatal health.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87802 is indicated for the screening of Streptococcus group B (Strep B) during pregnancy. This test is particularly important for the following conditions:

  • Pregnancy Screening The test is performed to identify the presence of Strep B in pregnant women, which is crucial for preventing potential infections in newborns.
  • Newborn Infection Risk Strep B can cause life-threatening infections in newborns, including pneumonia, meningitis, and sepsis, making early detection vital.
  • Maternal Health Concerns Pregnant women may also be at risk for serious infections such as urinary tract infections and skin infections due to Strep B.
  • Immunocompromised Individuals The test may be relevant for individuals with weakened immune systems who are at higher risk for infections caused by Strep B.

2. Procedure

The procedure for conducting the test under CPT® Code 87802 involves several detailed steps to ensure accurate detection of Strep B antigens:

  • Step 1: Specimen Collection A specimen is obtained by swabbing the cervix and the lower third of the vagina. This step is critical as it collects the necessary material for testing.
  • Step 2: Reagent Preparation The first of several reagents is introduced into an antigen extraction tube. This reagent is essential for preparing the specimen for antigen detection.
  • Step 3: Mixing the Specimen The swab containing the specimen is added to the antigen extraction tube, where it is mixed with the first reagent to facilitate the extraction of antigens.
  • Step 4: Additional Reagents A second reagent is added to the mixture and thoroughly mixed with the swab. The swab is then left in the solution for several minutes to allow for proper interaction.
  • Step 5: Further Processing After the incubation period, the swab is removed, and a third reagent is introduced to the solution, continuing the preparation for testing.
  • Step 6: Test Device Preparation A pipette is used to transfer the solution from the specimen tube to a test device, which is designed to facilitate the detection of the Strep B antigens.
  • Step 7: Washing the Surface The surface of the test device is washed with a fourth reagent to ensure that any non-specific binding is removed, enhancing the accuracy of the test.
  • Step 8: Substrate Application A drop of substrate is applied to the test device, followed by another wash to prepare for the final observation.
  • Step 9: Final Examination The test device is examined under bright light. If the test is positive, both a control spot and the test spot will change color, indicating the presence of Strep B antigens.

3. Post-Procedure

After the completion of the test, the results are interpreted based on the color change observed on the test device. A positive result indicates the presence of Strep B antigens, which may necessitate further clinical evaluation and management to protect both maternal and neonatal health. It is important for healthcare providers to communicate the results to the patient promptly and discuss any necessary follow-up actions or treatments. Additionally, proper documentation of the test results and any subsequent clinical decisions should be maintained for compliance and continuity of care.
Short Descr STREP B ASSAY W/OPTIC
Medium Descr IAADIADOO STREPTOCOCCUS GROUP B
Long Descr Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group B
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GW Service not related to the hospice patient's terminal condition
Date
Action
Notes
2022-01-01 Changed First appearance of change in codebook.
2021-01-01 Changed First appearance of change in CPT® Code Set.
2020-10-06 Changed Code changed.
2002-01-01 Added First appearance in code book in 2002.
Code
Description
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"